Senseonics, Ascensia launch Eversense 365 year-long CGM in the U.S.

October 1, 2024
9:31 am

Ascensia Diabetes Care announced today that it launched the Eversense 365 CGM system from Senseonics (NYSE:SENS) in the U.S.

Eversense 365, an implantable continuous glucose monitor (CGM), is indicated for people with type 1 and type 2 diabetes aged 18 years and older.

Senseonics announced last month that it received FDA clearance for Eversense 365. With the clearance, it became the world’s first 365-day CGM system, according to the company.

Senseonics, Ascensia launch Eversense 365 year-long CGM in the U.S.

Sign up for Blog Updates